Related references
Note: Only part of the references are listed.Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study
A. Cortelezzi et al.
LEUKEMIA (2009)
Alemtuzumab in clinical practice: A British Columbia experience
David Hui et al.
LEUKEMIA & LYMPHOMA (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Comprehensive genetic characterization of CLL:: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping
C. Haferlach et al.
LEUKEMIA (2007)
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2007)
The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia
N. E. Kay et al.
LEUKEMIA (2007)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia - A nation-wide retrospective study in Austria
Michael Fiegl et al.
CANCER (2006)
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
Tait D. Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzamab
Susan M. O'Brien et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
A. R. Pettitt et al.
LEUKEMIA (2006)
11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules
JD Dickinson et al.
LEUKEMIA & LYMPHOMA (2006)
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
LH Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
P Moreton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia
M Keating et al.
CLINICAL LYMPHOMA (2004)
Efficacy and tolerability of Alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia -: Change of regimen needed?
K Rieger et al.
LEUKEMIA & LYMPHOMA (2004)
Phase II study of alerntuzurnab in chronic lymphoproliferative disorders
A Ferrajoli et al.
CANCER (2003)
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
KR Rai et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
J Lundin et al.
BLOOD (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
The CD52 antigen and development of the CAMPATH antibodies
G Hale
CYTOTHERAPY (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
